Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target?: Effects of carbenoxolone in lean and obese Zucker rats

被引:81
作者
Livingstone, DEW [1 ]
Walker, BR [1 ]
机构
[1] Univ Edinburgh, Western Gen Hosp, Dept Med Sci, Endocrinol Unit, Edinburgh EH4 2XU, Midlothian, Scotland
关键词
D O I
10.1124/jpet.102.044842
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In liver and adipose tissue, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) regenerates glucocorticoids from inactive 11-keto metabolites. Pharmacological inhibition or transgenic disruption of 11beta-HSD1 attenuates glucocorticoid action and increases insulin sensitivity. Increased adipose 11beta-HSD1 may also contribute to the metabolic complications of obesity. Here, we examine the effects of inhibition of 11beta-HSDs with carbenoxolone in obese insulin-resistant Zucker rats, a strain in which tissue-specific dysregulation of 11beta-HSD1 ( increased in adipose, decreased in liver) mirrors changes in human obesity. Six-week-old male rats were treated orally with carbenoxolone ( 50 mg/kg/day) or water ( 1 ml/kg/day) for 3 weeks. Carbenoxolone inhibited 11beta-HSD1 activity in liver ( 25 +/- 3 versus 52 +/- 2% conversion in lean; 18 +/- 3 versus 35 +/- 3% in obese; p < 0.01) but not in adipose tissue or skeletal muscle. Carbenoxolone had no effect on weight gain or food intake, did not affect plasma glucose during an oral glucose tolerance test, and increased the plasma insulin response to glucose. However, high-density lipoprotein cholesterol was increased by carbenoxolone in obese animals (1.52 +/- 0.24 versus 1.21 +/- 0.26 mM; p < 0.03). Carbenoxolone did not inhibit hepatic inactivation of glucocorticoid by 5beta-reductase and had no significant effect on plasma corticosterone levels. In conclusion, carbenoxolone provides a model for liver-specific inhibition of 11beta-HSD1, which results in improved lipid profile, in Zucker obese rats. Failure to inhibit 11beta-HSD1 in adipose tissue and/or skeletal muscle may explain the lack of effect on glucose tolerance and obesity. Inhibition of adipose 11beta-HSD1 is probably necessary to gain the maximum benefit of an 11beta-HSD1 inhibitor.
引用
收藏
页码:167 / 172
页数:6
相关论文
共 50 条
[21]   Hippocampal 11β-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression has a diurnal variability that is lost in the obese Zucker rat [J].
Buren, Jonas ;
Bergstrom, Sven-Anders ;
Loh, Edmund ;
Soderstrom, Ingegerd ;
Olsson, Tommy ;
Mattsson, Cecilia .
ENDOCRINOLOGY, 2007, 148 (06) :2716-2722
[22]   Effects of Piper sarmentosum Water Extract on 11-β Hydroxysteroid Dehydrogenase Type 1 Bioactivity in Ovariectomy-Induced Obese Rats [J].
Azlina, A. Aida ;
Farihah, H. S. ;
Qodriyah, H. M. S. ;
Azlina, M. F. Nur .
INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2009, 5 (06) :362-369
[23]   Renal effects of leptin in lean and obese Zucker rats. [J].
Villarreal, D ;
Reams, G ;
Freeman, RH ;
Kahn, Z ;
Dale, S .
FASEB JOURNAL, 1998, 12 (05) :A684-A684
[24]   EFFECTS OF CCK ON GASTROINTESTINAL FUNCTION IN LEAN AND OBESE ZUCKER RATS [J].
MOOS, AB ;
MCLAUGHLIN, CL ;
BAILE, CA .
PEPTIDES, 1982, 3 (04) :619-622
[25]   11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases [J].
Kupczyk, Daria ;
Studzinska, Renata ;
Kolodziejska, Renata ;
Baumgart, Szymon ;
Modrzejewska, Martyna ;
Wozniak, Alina .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
[26]   The Crystal Structure of Murine 11β-hydroxysteroid Dehydrogenase 1: an Important Therapeutic Target for Diabetes [J].
Zhang, Jiandong ;
Osslund, Timothy D. ;
Plant, Matthew H. ;
Clogston, Christi L. ;
Nybo, Rebecca E. ;
Xiong, Fei ;
Delaney, John M. ;
Jordan, Steven R. .
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2005, 61 :C189-C189
[27]   Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1:: An important therapeutic target for diabetes [J].
Zhang, JD ;
Osslund, TD ;
Plant, MH ;
Clogston, CL ;
Nybo, RE ;
Xiong, F ;
Delaney, JM ;
Jordan, SR .
BIOCHEMISTRY, 2005, 44 (18) :6948-6957
[28]   11 β-hydroxysteroid dehydrogenase type 1 and obesity [J].
Morton, Nicholas M. ;
Seckl, Jonathan R. .
OBESITY AND METABOLISM, 2008, 36 :146-164
[29]   11β-hydroxysteroid dehydrogenase type 1 in obesity [J].
Walker, BR .
OBESITY RESEARCH, 2004, 12 (01) :1-3
[30]   11β-hydroxysteroid dehydrogenase type 1 inhibitors [J].
Boyle, Craig D. ;
Kowalski, Timothy J. ;
Zhang, Lili .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 41, 2006, 41 :127-140